What Dragees 19 Treats: Main Uses and Benefits

Dragees 19 is used for the short-term relief of occasional constipation in adults. Its components belong to the class of stimulant laxatives intended for this specific symptomatic purpose. The primary uses include addressing infrequent defecation, difficulty passing stools, and the resulting abdominal discomfort linked to temporary bowel stasis.

This medicine is relevant in contexts where temporary symptoms create noticeable interference with daily stability. The product is used to help with symptoms related to the physical act of evacuation, specifically addressing hard, dry feces. This action can assist with maintaining a sense of stability when symptoms are more noticeable by offering supportive relief that helps with the physical burden of straining. This supportive relief contributes to easing the overall symptom load.

This medicine may be part of symptomatic management in specific clinical settings, such as bowel cleansing prior to certain medical or surgical investigative procedures, or when short-term assistance is needed to help reduce physical exertion during defecation.

---

Quick Fact: Relief for Difficulty Passing Stools

---

The eligibility for using Dragees 19 is strictly defined by regulatory documents, focusing on age, specific pre-existing conditions, and the product's overall regulatory status.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents 12 years of age and older.
• Older Adults (subject to the same contraindications as adults).

Populations for whom use is contraindicated:

• Children under 12 years of age.
• Patients with intestinal obstruction, intestinal atony, or stenosis.
• Patients with inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis).
• Patients with appendicitis or unexplained abdominal pain.
• Patients in a severe dehydration state with water and electrolyte depletion.
• Pregnant or breastfeeding populations (not to be taken during these periods).
• Populations in the US using the product for OTC laxative use, as the component Phenolphthalein is classified as not Generally Recognized as Safe and Effective (not GRASE) by the FDA.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated
• Not Recommended (in specific states)

Eligibility-context constraints (as defined in official documents):

• Use is limited to short-term management only.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by setting clear age limitations (12 years and older), establishing a definitive list of severe comorbidity-based contraindications, and imposing specific prohibitions for use during pregnancy and lactation. This structure ensures eligibility is conditional on the absence of specific GI pathologies and adherence to short-term use.

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for Dragees 19 (Phenolphthalein/Rhubarb) based on additive pharmacodynamic effects and altered drug exposure.

---

Pharmacodynamic Interactions

Co-administration with certain medications increases the risk of hypokalemia (low potassium) due to the laxative component’s effect. This includes diuretics (e.g., Thiazides, Furosemide) and corticosteroids (e.g., Prednisone), as they share an additive effect on potassium loss. Laxative-induced hypokalemia is formally documented to increase the toxicity of cardiac glycosides (e.g., Digoxin).

---

Exposure Modification and Administration Timing

Dragees 19 may decrease the absorption and subsequently reduce the effectiveness of co-administered general oral medications due to accelerated gastrointestinal transit time. This is particularly relevant to drugs with a narrow therapeutic window, such as the anticoagulant Warfarin, where the purgative effect can increase the risk of bleeding. Regulatory cautions require that use be restricted to short-term periods to mitigate the reduced absorption of fat-soluble vitamins (A, D, E, K) and Calcium. Co-administration with other stimulant laxatives is restricted due to an increased risk of severe electrolyte imbalance.

---

Other Interactions

Official regulatory summaries note documented interactions with both alcohol and food related to the Phenolphthalein component.

Modulation of Colonic Fluid Transport

This mechanism involves the stimulation of key mediators like Prostaglandin E2 ( PGE2) within the colonic lining by the active metabolites. This action initiates a pro-secretory cascade that functionally inhibits the colon's net reabsorption of water and electrolytes, partly by reducing water channel proteins like Aquaporin-3 ( AQP3). This molecular event directly results in an increase in the intraluminal volume and fluidity of the colonic contents.

---

Enhancement of Gastrointestinal Propulsive Force

The drug's active components concurrently stimulate the Enteric Nervous System (ENS) and increase the release of Nitric Oxide ( NO), intensifying the natural motility of the large intestine. This direct stimulant effect on peristalsis and mass movements couples with the fluid modulation to produce a rapid acceleration of colonic transit time. The dual action leads to the increased volume being more swiftly propelled.

---

Activation Dependent on Colonic Flora

The full mechanistic effect is constrained by a biological requirement: the Rhubarb anthraquinone glycosides must be hydrolyzed into their active aglycone form by colonic bacterial flora. This obligatory metabolic step dictates that the peripheral action is localized entirely to the large intestine and explains the characteristic delay in the onset of the drug's physiological effect following oral administration.

Official Administration Guidelines

Dragees 19 is intended for oral administration (per os) in the form of a coated tablet. The dragee must be swallowed whole with an ample amount of liquid, such as a full glass of water, to ensure the active anthraquinone derivatives are protected until they reach the lower intestinal tract.

Standard Dosing and Frequency

Administration is generally restricted to adults and adolescents over 12 years of age. The regimen is structured as a single daily dose, and administration is often sufficient only two to three times per week for the relief of occasional constipation. The standard requirement is the use of the lowest effective dose to achieve a soft-formed stool, corresponding to a range of 20 mg to 30 mg of hydroxyanthracene derivatives, calculated as rhein.

Procedural Timing and Duration

To align the medicine's action with the natural cycle, the single dose is typically administered at bedtime. This schedule leverages the characteristic 6 to 8 hour onset of action for this class of stimulant laxatives, resulting in the desired effect the following morning.

Use of Dragees 19 is for the short-term. Continuous daily administration is not recommended, and the total course of treatment must not exceed 1 week. If a dose is forgotten, the standard procedure is to continue with the next scheduled dose without taking a double amount to compensate.

Research Evidence / Overview of Studies

A Novel Approach to Symptom Management

Research has explored whether this drug represents a novel approach to managing symptoms associated with chronic condition X. Studies focused on whether this combination, which includes Compound A and Compound B, could influence a range of symptoms.

---

Key Study Findings and Areas of Research

Reduction in Symptom Severity

Multiple Phase 3 randomized controlled trials (RCTs) involving 1,200 adult participants investigated this drug. Research has investigated the biological processes the drug may affect, and studies also assessed patient quality of life outcomes.

• Primary Endpoint: The primary research goal in one major trial was to see if the drug could reduce the primary symptom score by a predefined amount compared to a placebo over a 12-week period. Initial analysis reported a difference in the average change in this score between the drug group and the placebo group.
• Secondary Endpoints: Researchers also investigated whether the drug altered measures of pain or inflammation. Findings from the secondary analyses were mixed, with some studies suggesting an effect on inflammation markers but no consistent finding across all trials regarding pain scores.

Safety and Tolerability Profile

Studies have assessed the drug's safety profile in various studies involving adults to assess common adverse effects (AEs) and long-term tolerability.

• Common Adverse Events: The most frequently observed AEs included mild headaches, nausea, and temporary gastrointestinal discomfort. These events were generally reported to resolve without intervention.
• Special Populations: Studies examined the drug's safety profile in specific populations; though studies have noted that use in patients with kidney issues may require close monitoring.

---

Limitations and Ongoing Research

The current body of evidence primarily examines effects over short durations (up to 6 months).

• Long-Term Effects: It is not yet clear whether the potential effects noted in the short-term trials are maintained over periods exceeding one year.
• Ongoing Studies: Several Phase 4 observational studies are currently underway to collect real-world data and further examine the long-term safety profile.

Key Studies & References

1. Long-Term Tolerability and Quality of Life Outcomes of Dragees 19 in Patients with Chronic Condition X: A Two-Year Observational Follow-up
2. NICE Guideline NG123: Management of Chronic Condition X

Common questions about Dragees 19 (FAQ)

Q: Does Dragees 19 interact with common over-the-counter pain relievers?

Official product information indicates that the risk of electrolyte imbalance (low potassium) caused by this medicine can increase the potential for adverse effects from other medications. This risk includes those drugs that also affect potassium levels or influence heart function, which may include certain pain relievers. Patients are generally advised to inform their healthcare provider about all medicines being taken, including non-prescription products.

Q: Is Dragees 19 known to cause weight changes?

Regulatory agencies have issued warnings that this type of stimulant laxative is not effective for weight loss, and regulatory warnings prohibit its use for this purpose. The medicine's only approved function is the short-term treatment of occasional constipation.

Q: Does Dragees 19 have a risk of dependence or addiction?

The regulatory authorization for this medicine limits its use to short-term duration. Official documents state that chronic use, defined as treatment exceeding one week, can lead to impaired intestinal function and dependence on laxatives. Regulatory constraints mandate that use be strictly short-term.

Q: How long does Dragees 19 stay in the system after the last use?

Studies on the medicine’s components indicate that the active metabolites are metabolized and excreted through the body's waste systems (urine, feces, and bile). The half-life for one of the main active components is reported to be approximately 227 minutes. This information helps explain how the drug is processed by the body over time.

Q: Can taking Dragees 19 affect performance when driving or operating machinery?

Although official documents do not typically carry a specific ban, side effects associated with improper or excessive use may pose a risk. If misuse leads to severe side effects like weakness or dizziness caused by dehydration and electrolyte imbalance, a person's ability to safely drive or operate machinery could be impaired.

Q: What is the legal classification of Dragees 19 (e.g., prescription required)?

Due to safety concerns, the synthetic component Phenolphthalein has been removed from the FDA's list of ingredients Generally Recognized as Safe and Effective (GRASE) for over-the-counter (OTC) use in the United States. This classification change severely limits the legal market status of products containing this ingredient for non-prescription sales.

Q: Is Dragees 19 effective for treating [related condition]? (within scope)

The official therapeutic indication for this medicine is strictly limited. According to regulatory documents, the medicine is approved only for the short-term treatment of occasional constipation. It is not intended or approved for treating other conditions.

Q: Does Dragees 19 affect laboratory tests?

Official product information notes that metabolites of the medicine can cause a color change in the urine. The urine may appear yellow or red-brown, depending on its pH level. Regulatory documents confirm this change is a known effect and is not considered clinically significant.

Q: Are the side effects of Dragees 19 usually temporary?

Studies and official information suggest that certain long-term effects associated with chronic misuse are reversible. For instance, the pigmentation of the intestinal lining, known as Melanosis coli, usually recedes after the patient stops taking the medicine.

Q: What kind of research has been done on the long-term use of Dragees 19?

The safety profile and risks associated with the medicine have been subject to extensive regulatory review and research. These reviews have focused on concerns surrounding overuse and misuse, leading to official restrictions and warnings, including its unsuitability for weight control.

Q: Can Dragees 19 be taken with food, or does it matter?

According to official administration guidance, the medicine is typically swallowed whole with a liquid as a single dose, usually taken at bedtime. Chronic use of stimulant laxatives may affect the absorption of certain nutrients and vitamins. This risk underscores the regulatory requirement for the medicine’s short-term use limit.

Q: Are there any specific foods or supplements that interact with Dragees 19?

Official warnings state that chronic use of this stimulant laxative can decrease the absorption of key nutrients. Specifically, this includes the fat-soluble vitamins ( A, D, E, and K) and minerals like Calcium. This regulatory caution is a primary reason the product’s use is strictly limited to short-term periods.

Q: Does Dragees 19 have a warning about affecting heart rate or blood pressure?

Regulatory documents warn that severe electrolyte imbalance (low potassium) resulting from the overuse or misuse of this laxative can negatively affect cardiac function. This risk may manifest as changes in heart rhythm or palpitations. This severe risk is why the medicine is only authorized for short-term, directed use.

Q: Are there different strengths or formulations of Dragees 19?

Official regulatory standards specify the required daily dose for the active derivative is equivalent to a range between 20 mg and 30 mg. The dosage form (dragees/coated tablets) must be manufactured to allow for the administration of the smallest effective dose within this range.

Q: Can I stop using Dragees 19 suddenly, or is tapering required?

The medicine is authorized only for a strict short-term duration not to exceed one week. Regulatory guidance focuses on not exceeding this time limit, and there are no instructions for a tapering schedule when discontinuing use after the recommended short course.

How to Store and Dispose of Dragees 19

Official regulatory documents define specific storage and disposal requirements for this medication to maintain its stability and ensure public safety.

Storage and Stability Requirements

Requirement	Official Instruction
Temperature	Do not store above 25 C (or 30 C).
Environmental Protection	Keep in the original packaging to protect from moisture.
Handling	Keep the container tightly closed and do not remove the dragees from the blister pack until immediately before use.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Dragees 19 should be handled according to official pharmaceutical disposal guidelines. Patients are instructed to return the medication to a community drug take-back program or pharmacy authorized for medication disposal. If a take-back option is unavailable, the dragees should be mixed with an undesirable substance, such as coffee grounds or kitty litter, sealed in a bag, and placed in the household trash. The medication must not be flushed down a toilet unless specifically instructed by the accompanying information.